Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Leukemia

  Free Subscription


Articles published in Leukemia

Retrieve available abstracts of 341 articles:
HTML format



Single Articles


    June 2025
  1. VIT F, Bittolo T, Zucchetto A, Papotti R, et al
    Measurement of Immunoglobulin Intraclonal diversification refines the clinical impact of IGHV mutational status in chronic lymphocytic leukemia.
    Leukemia. 2025 Jun 18. doi: 10.1038/s41375-025-02650.
    PubMed     Abstract available


  2. IKOMA Y, Nakamura N, Kaneda Y, Takamori H, et al
    Impact of myelodysplasia-related gene mutations and residual mutations at remission in venetoclax/azacitidine for AML.
    Leukemia. 2025;39:1362-1367.
    PubMed     Abstract available


  3. BUCKLEY M, Yeung DT, White DL, Eadie LN, et al
    T-cell acute lymphoblastic leukaemia: subtype prevalence, clinical outcome, and emerging targeted treatments.
    Leukemia. 2025;39:1294-1310.
    PubMed     Abstract available


  4. VELETIC I, Harris DM, Rozovski U, Bertilaccio MTS, et al
    CLL cell-derived exosomes alter the immune and hematopoietic systems.
    Leukemia. 2025;39:1380-1394.
    PubMed     Abstract available


    May 2025
  5. ZHANG Y, Feng Z, Du J, Liu H, et al
    High-dose cytarabine with idarubicin consolidation for acute myeloid leukemia in first complete remission: a randomized controlled trial.
    Leukemia. 2025 May 28. doi: 10.1038/s41375-025-02655.
    PubMed     Abstract available


  6. BOHRA A, Hassan R, Zanwar S, Jevremovic D, et al
    Peripheral Blood Flow Cytometry-based Definition of Plasma Cell Leukemia.
    Leukemia. 2025 May 26. doi: 10.1038/s41375-025-02653.
    PubMed    


  7. DEMBITZ V, James SC, Gallipoli P
    Targeting lipid metabolism in acute myeloid leukemia: biological insights and therapeutic opportunities.
    Leukemia. 2025 May 22. doi: 10.1038/s41375-025-02645.
    PubMed     Abstract available


  8. AUER F, Morcos MNF, Sipola M, Akhtar I, et al
    Trajectories from single-cells to PAX5-driven leukemia reveal PAX5-MYC interplay in vivo.
    Leukemia. 2025 May 20. doi: 10.1038/s41375-025-02626.
    PubMed     Abstract available


  9. KUHN MWM, Pemmaraju N, Heidel FH
    The evolving landscape of epigenetic target molecules and therapies in myeloid cancers: focus on acute myeloid leukemia and myeloproliferative neoplasms.
    Leukemia. 2025 May 15. doi: 10.1038/s41375-025-02639.
    PubMed     Abstract available


  10. NGUYEN NTK, Yao H, Hosokawa K, Esaki Y, et al
    Acute myeloid leukemia stem cells remodel the bone marrow niche via TGF-beta-activated Alcam(+) bone lining cells, creating a self-sustaining environment.
    Leukemia. 2025 May 13. doi: 10.1038/s41375-025-02640.
    PubMed    


  11. WANG'ONDU RW, Ashcraft E, Chang TC, Roberts KG, et al
    Heterogeneity of IKZF1 genomic alterations and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia.
    Leukemia. 2025 May 13. doi: 10.1038/s41375-025-02633.
    PubMed     Abstract available


  12. BATALLER A, Goulart HE, Issa GC, DiNardo CD, et al
    Characteristics and outcomes of newly diagnosed acute myeloid Leukemia with KMT2A rearrangements.
    Leukemia. 2025 May 9. doi: 10.1038/s41375-025-02634.
    PubMed     Abstract available


  13. IZUMI S, Ohtani K, Matsumoto M, Shibata S, et al
    Regulation of H3K4me3 breadth and MYC expression by the SETD1B catalytic domain in MLL-rearranged leukemia.
    Leukemia. 2025 May 8. doi: 10.1038/s41375-025-02638.
    PubMed     Abstract available


  14. NGUYEN LXT, Zhang B, Hoang DH, Zhao D, et al
    Correction: Cytoplasmic DROSHA and non-canonical mechanisms of MiR-155 biogenesis in FLT3-ITD acute myeloid leukemia.
    Leukemia. 2025 May 5. doi: 10.1038/s41375-025-02637.
    PubMed    


  15. LAUSEKER M, Hoffmann VS, Pfirrmann M
    Prognostic scoring systems in chronic myeloid leukaemia.
    Leukemia. 2025;39:1046-1052.
    PubMed     Abstract available


  16. TAKAMORI H, Huang YJ, Fukushima H, Yokoyama K, et al
    Whole-genome sequencing of myeloproliferative neoplasms revealed dynamic clonal changes in the fibrotic or leukemic transformation and novel FOXP1 mutations in the fibrotic transformation.
    Leukemia. 2025;39:1218-1227.
    PubMed     Abstract available


    April 2025
  17. HASAN MK, Widhopf Ii GF, Ghia EM, Kipps TJ, et al
    Wnt5a induces ROR1 dependent NF-kappaB activation to enhance MMP-9 expression and invasiveness in chronic lymphocytic leukemia.
    Leukemia. 2025 Apr 28. doi: 10.1038/s41375-025-02616.
    PubMed     Abstract available


  18. MECKLENBRAUCK R, Borchert N, Gabdoulline R, Poll P, et al
    Prognostic impact of clonal representation of myelodysplasia-related gene mutations in acute myeloid leukemia.
    Leukemia. 2025 Apr 28. doi: 10.1038/s41375-025-02622.
    PubMed    


  19. KRIZKOVA J, Polivkova V, Laznicka A, Curik N, et al
    Somatic mutations and outcomes in chronic myeloid leukemia adolescent and young adults compared to children, adults, and BCR::ABL1-positive acute lymphoblastic leukemia.
    Leukemia. 2025 Apr 28. doi: 10.1038/s41375-025-02609.
    PubMed     Abstract available


  20. GHANI F, Zubair AC
    Possible impacts of cosmic radiation on leukemia development during human deep space exploration.
    Leukemia. 2025 Apr 24. doi: 10.1038/s41375-025-02624.
    PubMed     Abstract available


  21. THORVALDSDOTTIR B, Mansouri L, Sutton LA, Nadeu F, et al
    ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker.
    Leukemia. 2025 Apr 24. doi: 10.1038/s41375-025-02615.
    PubMed     Abstract available


  22. ZHOU T, Short NJ, Jain N, Patel KP, et al
    Age-related prognoses of genetic subtypes in B-cell acute lymphoblastic leukemia/lymphoma (B-ALL): insights from a decade of national data.
    Leukemia. 2025 Apr 24. doi: 10.1038/s41375-025-02588.
    PubMed    


  23. WU JF, Feliciano EJG, Singh A, Tremblay D, et al
    National cancer system metrics and leukemia outcomes: an analysis of global data for pediatric and adult patients.
    Leukemia. 2025 Apr 23. doi: 10.1038/s41375-025-02598.
    PubMed    


  24. SHIMA Y, Yamagata K, Kuroki Y, Sasaki K, et al
    Loss of NOL10 leads to impaired disease progression of NUP98::DDX10 leukemia.
    Leukemia. 2025 Apr 22. doi: 10.1038/s41375-025-02607.
    PubMed     Abstract available


  25. ASHAYE A, Shi L, Aldoss I, Montesinos P, et al
    Patient-reported outcomes in Philadelphia chromosome-positive acute lymphoblastic leukemia patients treated with ponatinib or imatinib: results from the PhALLCON trial.
    Leukemia. 2025 Apr 16. doi: 10.1038/s41375-025-02608.
    PubMed     Abstract available


  26. XU Y, Mou J, Wang Y, Zhou W, et al
    Correction: Regulatory T cells promote the stemness of leukemia stem cells through IL10 cytokine-related signaling pathway.
    Leukemia. 2025 Apr 15. doi: 10.1038/s41375-025-02618.
    PubMed    


  27. NIEDERMAYER A, Stursberg J, Bergmann AK, Zimmermann M, et al
    Remission induction in refractory, drug resistant pediatric PICALM::MLLT10+ B-cell acute lymphoblastic leukemia by venetoclax.
    Leukemia. 2025 Apr 15. doi: 10.1038/s41375-025-02591.
    PubMed    


  28. DECHOW A, Timonen S, Ianevski A, Jiang Q, et al
    Dual STAT3/STAT5 inhibition as a novel treatment strategy in T-prolymphocytic leukemia.
    Leukemia. 2025 Apr 15. doi: 10.1038/s41375-025-02577.
    PubMed     Abstract available


  29. HSU CJ, Schraw JM, Desrosiers TA, Janitz AE, et al
    All genetic subtypes of B-cell acute lymphoblastic leukemia exhibit increased incidence rates in children with Down syndrome.
    Leukemia. 2025 Apr 11. doi: 10.1038/s41375-025-02602.
    PubMed    


  30. XING C, Zhang H, Zheng M, Lu Q, et al
    Fabp4 is essential for the maintenance of leukemia stem cells while sparing hematopoietic stem cells.
    Leukemia. 2025 Apr 10. doi: 10.1038/s41375-025-02568.
    PubMed    


  31. CORTES JE, Lang F, Rea D, Hochhaus A, et al
    Asciminib in combination with imatinib, nilotinib, or dasatinib in patients with chronic myeloid leukemia in chronic or accelerated phase: phase 1 study final results.
    Leukemia. 2025 Apr 9. doi: 10.1038/s41375-025-02592.
    PubMed     Abstract available


  32. KAYA F, Bewicke-Copley F, Miettinen JJ, Casado P, et al
    DEK::NUP214 acts as an XPO1-dependent transcriptional activator of essential leukemia genes.
    Leukemia. 2025 Apr 9. doi: 10.1038/s41375-025-02593.
    PubMed     Abstract available


  33. HOCHHAUS A, Kim DW, Cortes JE, Sasaki K, et al
    Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1(T315I) treated with at least 2 prior TKIs: Phase 1 final results.
    Leukemia. 2025 Apr 9. doi: 10.1038/s41375-025-02578.
    PubMed     Abstract available


  34. PAGANO L, Maschmeyer G, Lamoth F, Blennow O, et al
    Primary antifungal prophylaxis in hematological malignancies. Updated clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL).
    Leukemia. 2025 Apr 9. doi: 10.1038/s41375-025-02586.
    PubMed     Abstract available


  35. REINHARDT C, Ochsenbein AF
    Immune checkpoints regulate acute myeloid leukemia stem cells.
    Leukemia. 2025 Apr 2. doi: 10.1038/s41375-025-02566.
    PubMed     Abstract available


  36. LI R, Wu X, Xue K, Wu S, et al
    CircTADA2A stabilizes p53 via interacting with TRIM28 and suppresses the maintenance of FLT3-ITD acute myeloid leukemia.
    Leukemia. 2025 Apr 2. doi: 10.1038/s41375-025-02589.
    PubMed     Abstract available


  37. BUSSOT L, Poulain S, Nudel Ortmans M, Davi F, et al
    Targeted therapies overcome the poor prognosis of stereotyped Subset#2 chronic lymphocytic leukemia : a real-world multicentric study.
    Leukemia. 2025 Apr 1. doi: 10.1038/s41375-025-02555.
    PubMed    


  38. HUANG J, Xie J, Wang Y, Sheng M, et al
    STING mediates increased self-renewal and lineage skewing in DNMT3A-mutated hematopoietic stem/progenitor cells.
    Leukemia. 2025;39:929-941.
    PubMed     Abstract available


  39. SHI C, Tian Z, Yan J, Zhang M, et al
    Immunotherapy targeting a leader sequence cathepsin G-derived peptide.
    Leukemia. 2025;39:888-898.
    PubMed     Abstract available


    March 2025
  40. AYYADEVARA VSSA, Wertheim G, Gaur S, Chukinas JA, et al
    DYRK1A inhibition results in MYC and ERK activation rendering KMT2A-R acute lymphoblastic leukemia cells sensitive to BCL2 inhibition.
    Leukemia. 2025 Mar 27. doi: 10.1038/s41375-025-02575.
    PubMed     Abstract available


  41. CHARLES CANO F, Kloos A, Hebalkar RY, Plenge T, et al
    XPO1-dependency of DEK::NUP214 leukemia.
    Leukemia. 2025 Mar 27. doi: 10.1038/s41375-025-02570.
    PubMed     Abstract available


  42. JERKEMAN M, Mellgren K, Sonnevi K, Lisak M, et al
    Implementation of standard of care CAR-T-cell treatment for patients with aggressive B-cell lymphoma and acute lymphoblastic leukemia in Sweden.
    Leukemia. 2025 Mar 26. doi: 10.1038/s41375-025-02573.
    PubMed    


  43. STOLTZE U, Junk SV, Byrjalsen A, Cave H, et al
    Overt and covert genetic causes of pediatric acute lymphoblastic leukemia.
    Leukemia. 2025 Mar 24. doi: 10.1038/s41375-025-02535.
    PubMed     Abstract available


  44. GEYER J, Opoku KB, Lin J, Ramkissoon L, et al
    Real-time genomic characterization of pediatric acute leukemia using adaptive sampling.
    Leukemia. 2025 Mar 24. doi: 10.1038/s41375-025-02565.
    PubMed     Abstract available


  45. COLE FM, Laszlo GS, Lunn-Halbert MC, Kehret AR, et al
    Preclinical characterization of the anti-leukemia activity of the CD123 antibody-drug conjugate, pivekimab sunirine (IMGN632).
    Leukemia. 2025 Mar 21. doi: 10.1038/s41375-025-02571.
    PubMed    


  46. ROMPIETTI C, Adamo FM, Sorcini D, De Falco F, et al
    Bcor loss promotes Richter transformation of chronic lymphocytic leukemia associated with Notch1 activation in mice.
    Leukemia. 2025 Mar 20. doi: 10.1038/s41375-025-02557.
    PubMed     Abstract available


  47. SHAH BD, Cassaday RD, Park JH, Houot R, et al
    Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3.
    Leukemia. 2025 Mar 19. doi: 10.1038/s41375-025-02532.
    PubMed     Abstract available


  48. SPERB N, Maksakova IA, Escano L, Abraham L, et al
    The proto-oncogenic miR-106a-363 cluster enhances adverse risk acute myeloid leukemia through mitochondrial activation.
    Leukemia. 2025 Mar 17. doi: 10.1038/s41375-025-02558.
    PubMed     Abstract available


  49. WANG H, Suo S, Li D, Li J, et al
    Comparison of subcutaneous injection versus intravenous infusion of cytarabine for induction therapy in adult acute myeloid leukemia.
    Leukemia. 2025 Mar 12. doi: 10.1038/s41375-025-02556.
    PubMed    


  50. KLEPZIG H, Herling M, Pflug N, Braun T, et al
    Models for T-large granular lymphocytic leukemia: how to mimic the cellular interplays in malignant autoimmunity.
    Leukemia. 2025 Mar 7. doi: 10.1038/s41375-025-02553.
    PubMed     Abstract available


  51. MILLOT F, Ampatzidou M, Moulik NR, Tewari S, et al
    Management of children and adolescents with chronic myeloid leukemia in chronic phase: International pediatric chronic myeloid leukemia expert panel recommendations.
    Leukemia. 2025 Mar 5. doi: 10.1038/s41375-025-02543.
    PubMed     Abstract available


  52. LIPTON JH, Rea D
    Living, not just surviving, with chronic myeloid leukemia - quality of life to the front of the line.
    Leukemia. 2025 Mar 5. doi: 10.1038/s41375-025-02548.
    PubMed    


  53. BRUNMEIR R, Ying L, Yan J, Hee YT, et al
    EZH2 modulates mRNA splicing and exerts part of its oncogenic function through repression of splicing factors in CML.
    Leukemia. 2025;39:650-662.
    PubMed     Abstract available


    February 2025
  54. REUVEKAMP T, Ngai LL, den Hartog D, Carbaat-Ham J, et al
    CD34+CD38- leukemia stem cells predict clinical outcomes in acute myeloid leukemia patients treated non-intensively with hypomethylating agents.
    Leukemia. 2025 Feb 27. doi: 10.1038/s41375-025-02539.
    PubMed    


  55. DINARDO CD, Jen WY, Takahashi K, Kadia TM, et al
    Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia.
    Leukemia. 2025 Feb 25. doi: 10.1038/s41375-025-02531.
    PubMed     Abstract available


  56. GIUDICE V, Selleri C
    How fast does leukemia progress?
    Leukemia. 2025 Feb 24. doi: 10.1038/s41375-025-02536.
    PubMed    


  57. MINAMI M, Sakoda T, Kawano G, Kochi Y, et al
    Distinct leukemogenic mechanism of acute promyelocytic leukemia based on genomic structure of PML::RARalpha.
    Leukemia. 2025 Feb 20. doi: 10.1038/s41375-025-02530.
    PubMed     Abstract available


  58. HORMANN FM, Rudd SG
    Nelarabine in T-cell acute lymphoblastic leukemia: intracellular metabolism and molecular mode-of-action.
    Leukemia. 2025 Feb 17. doi: 10.1038/s41375-025-02529.
    PubMed     Abstract available


  59. ABEDIN SM, Guru Murthy GS, Hamadani M, Michaelis LC, et al
    Phase 1 study of lintuzumab-Ac225 combined with CLAG-M salvage therapy in relapsed/refractory acute myeloid leukemia.
    Leukemia. 2025 Feb 15. doi: 10.1038/s41375-025-02528.
    PubMed     Abstract available


  60. OKABE S, Arai Y, Gotoh A
    Correspondence to: "Combination therapies with ponatinib and asciminib in a preclinical model of chronic myeloid leukemia blast crisis with compound mutations", Curik N et al. Leukemia. 2024; 38: 1415-1418.
    Leukemia. 2025 Feb 6. doi: 10.1038/s41375-025-02521.
    PubMed    


  61. SU Y, Han Z, Ji Y, Liu A, et al
    Patterns and variations of copy number alterations in acute myeloid leukemia: insights from the LeukAtlas database.
    Leukemia. 2025 Feb 2. doi: 10.1038/s41375-025-02514.
    PubMed     Abstract available


  62. FALINI B, Sorcini D, Perriello VM, Sportoletti P, et al
    Functions of the native NPM1 protein and its leukemic mutant.
    Leukemia. 2025;39:276-290.
    PubMed     Abstract available


  63. YANG S, Zhang X, Gale RP, Huang X, et al
    Is there really an accelerated phase of chronic myeloid leukaemia at presentation?
    Leukemia. 2025;39:391-399.
    PubMed     Abstract available


  64. CALVO J, Naguibneva I, Kypraios A, Gilain F, et al
    High CD44 expression and enhanced E-selectin binding identified as biomarkers of chemoresistant leukemic cells in human T-ALL.
    Leukemia. 2025;39:323-336.
    PubMed     Abstract available


  65. ORTI G, Peczynski C, Boreland W, O'Reilly M, et al
    Graft-versus-host disease after anti-CD19 chimeric antigen receptor T-cell therapy following allogeneic hematopoietic cell transplantation: a transplant complications and paediatric diseases working parties joint EBMT study.
    Leukemia. 2025;39:431-437.
    PubMed     Abstract available


    January 2025
  66. ABLE M, Kasper MA, Vick B, Schwach J, et al
    Effective eradication of acute myeloid leukemia stem cells with FLT3-directed antibody-drug conjugates.
    Leukemia. 2025 Jan 27. doi: 10.1038/s41375-024-02510.
    PubMed     Abstract available


  67. LIU J, Kharazmi E, Liang Q, Chen Y, et al
    Maternal weight during pregnancy and risk of childhood acute lymphoblastic leukemia in offspring.
    Leukemia. 2025 Jan 26. doi: 10.1038/s41375-025-02517.
    PubMed     Abstract available


  68. TREMBLAY CS, Saw J, Yan F, Boyle JA, et al
    Targeting LMO2-induced autocrine FLT3 signaling to overcome chemoresistance in early T-cell precursor acute lymphoblastic leukemia.
    Leukemia. 2025 Jan 23. doi: 10.1038/s41375-024-02491.
    PubMed     Abstract available


  69. LAUWEREINS L, Van Thillo Q, Demeyer S, Mentens N, et al
    TLE4 is a repressor of the oncogenic activity of TLX3 in T-cell acute lymphoblastic leukemia.
    Leukemia. 2025 Jan 21. doi: 10.1038/s41375-025-02513.
    PubMed     Abstract available


  70. ADDINSELL HM, Cant R, Hull NJ, Wang YH, et al
    Multi-omic analysis of chronic myelomonocytic leukemia monocytes reveals metabolic and immune dysregulation leading to altered macrophage polarization.
    Leukemia. 2025 Jan 15. doi: 10.1038/s41375-024-02511.
    PubMed    


  71. ANABTAWI N, Nicolet D, Alotaibi N, Buelow DR, et al
    Prognostic, biological, and structural implications of FLT3-JMD point mutations in acute myeloid leukemia: an analysis of Alliance studies.
    Leukemia. 2025 Jan 13. doi: 10.1038/s41375-024-02498.
    PubMed     Abstract available


  72. SHAHSWAR R, Gabdoulline R, Krueger K, Wichmann M, et al
    A novel prognostic risk model for patients with refractory/relapsed acute myeloid leukemia receiving venetoclax plus hypomethylating agents.
    Leukemia. 2025 Jan 8. doi: 10.1038/s41375-024-02501.
    PubMed     Abstract available


  73. SHIMOSATO Y, Yamamoto K, Jia Y, Zhang W, et al
    NPM1-fusion proteins promote myeloid leukemogenesis through XPO1-dependent HOX activation.
    Leukemia. 2025;39:75-86.
    PubMed     Abstract available


  74. STRULLU M, Caye-Eude A, Robert E, Renard JM, et al
    CD36 cell surface expression as a surrogate marker to identify ABL/JAK-class kinase fusions in pediatric BCP-ALL.
    Leukemia. 2025;39:64-74.
    PubMed     Abstract available


  75. JACOBY MA, Duncavage ED, Khanna A, Chang GS, et al
    Monitoring clonal burden as an alternative to blast count for myelodysplastic neoplasm treatment response.
    Leukemia. 2025;39:166-177.
    PubMed     Abstract available


  76. LI Z, Fierstein S, Tanaka-Yano M, Frenis K, et al
    The epigenetic state of the cell of origin defines mechanisms of leukemogenesis.
    Leukemia. 2025;39:87-97.
    PubMed     Abstract available


    December 2024
  77. SHI Z, Li J, Ding J, Zhang Y, et al
    ADAR1 is required for acute myeloid leukemia cell survival by modulating post-transcriptional Wnt signaling through impairing miRNA biogenesis.
    Leukemia. 2024 Dec 19. doi: 10.1038/s41375-024-02500.
    PubMed     Abstract available


  78. NABKI J, Al Deeban B, Sium AM, Cosentino C, et al
    Immunoglobulin light chain mutational status refines IGHV prognostic value in identifying chronic lymphocytic leukemia patients with early treatment requirement.
    Leukemia. 2024 Dec 17. doi: 10.1038/s41375-024-02499.
    PubMed     Abstract available


  79. BALESTRA T, Niswander LM, Bagashev A, Loftus JP, et al
    Co-targeting of the thymic stromal lymphopoietin receptor to decrease immunotherapeutic resistance in CRLF2-rearranged Ph-like and Down syndrome acute lymphoblastic leukemia.
    Leukemia. 2024 Dec 16. doi: 10.1038/s41375-024-02493.
    PubMed     Abstract available


  80. ORVAIN C, Milano F, Rodriguez-Arboli E, Othus M, et al
    Relationship between donor source, pre-transplant measurable residual disease, and outcome after allografting for adults with acute myeloid leukemia.
    Leukemia. 2024 Dec 12. doi: 10.1038/s41375-024-02497.
    PubMed     Abstract available


  81. GERRITSEN M, In 't Hout FEM, Knops R, Mandos BLR, et al
    Acute myeloid leukemia associated RUNX1 variants induce aberrant expression of transcription factor TCF4.
    Leukemia. 2024 Dec 12. doi: 10.1038/s41375-024-02470.
    PubMed    


  82. SHIMA H, Tono C, Tanizawa A, Ito M, et al
    Growth retardation and adult height in pediatric patients with chronic-phase chronic myeloid leukemia treated with tyrosine kinase inhibitors.
    Leukemia. 2024 Dec 12. doi: 10.1038/s41375-024-02488.
    PubMed    


  83. ARGYRIADI EA, Steffen IG, Chen-Santel C, Lissat A, et al
    Prognostic relevance of treatment deviations in children with relapsed acute lymphoblastic leukemia who were treated in the ALL-REZ BFM 2002 study.
    Leukemia. 2024 Dec 11. doi: 10.1038/s41375-024-02474.
    PubMed     Abstract available


  84. MITSUYUKI S, Shimomura Y, Mizumaki H, Yanada M, et al
    Allogeneic hematopoietic stem cell transplantation in adult acute myeloid leukemia with t(16;21)(p11;q22)/FUS::ERG.
    Leukemia. 2024 Dec 10. doi: 10.1038/s41375-024-02495.
    PubMed    


  85. HAMPEL PJ, Rabe KG, Wang Y, Hwang SR, et al
    Incidence of Richter transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma in the targeted therapy era.
    Leukemia. 2024 Dec 10. doi: 10.1038/s41375-024-02492.
    PubMed    


  86. ARZA-APALATEGI S, Heuts BMH, Bergevoet SM, Meering R, et al
    HMX3 is a critical vulnerability in MECOM-negative KMT2A::MLLT3 acute myelomonocytic leukemia.
    Leukemia. 2024 Dec 4. doi: 10.1038/s41375-024-02485.
    PubMed     Abstract available


  87. SHARMAN JP, Egyed M, Jurczak W, Skarbnik A, et al
    Correction: Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naive chronic lymphocytic leukemia.
    Leukemia. 2024 Dec 3. doi: 10.1038/s41375-024-02487.
    PubMed    


  88. WALTER W, Nadarajah N, Hutter S, Muller H, et al
    Characterization of myeloproliferative neoplasms based on genetics only and prognostication of transformation to blast phase.
    Leukemia. 2024;38:2644-2652.
    PubMed     Abstract available


  89. HALILOVIC M, Abdelsalam M, Zabkiewicz J, Lazenby M, et al
    Selective degradation of mutant FMS-like tyrosine kinase-3 requires BIM-dependent depletion of heat shock proteins.
    Leukemia. 2024;38:2561-2572.
    PubMed     Abstract available


    November 2024
  90. LOU J, Zhang Y, Tao J, Jin W, et al
    Infection-related pathway activation and vulnerability to arsenic trioxide in acute promyelocytic leukemia with TTMV::RARA.
    Leukemia. 2024 Nov 28. doi: 10.1038/s41375-024-02481.
    PubMed    


  91. HEGDE M, Ahmad MH, Mulet Lazaro R, Sugita M, et al
    The co-receptor Neuropilin-1 enhances proliferation in inv(16) acute myeloid leukemia via VEGF signaling.
    Leukemia. 2024 Nov 21. doi: 10.1038/s41375-024-02471.
    PubMed     Abstract available


  92. KAWASHIMA N, Gurnari C, Bravo-Perez C, Kubota Y, et al
    Clonal hematopoiesis in large granular lymphocytic leukemia.
    Leukemia. 2024 Nov 21. doi: 10.1038/s41375-024-02460.
    PubMed     Abstract available


  93. DALTVEIT DS, Morgan E, Colombet M, Steliarova-Foucher E, et al
    Global patterns of leukemia by subtype, age, and sex in 185 countries in 2022.
    Leukemia. 2024 Nov 20. doi: 10.1038/s41375-024-02452.
    PubMed     Abstract available


  94. KRISHNAMOORTHY V, Daly J, Kim J, Piatnitca L, et al
    The glycosyltransferase ST3GAL4 drives immune evasion in acute myeloid leukemia by synthesizing ligands for the glyco-immune checkpoint receptor Siglec-9.
    Leukemia. 2024 Nov 17. doi: 10.1038/s41375-024-02454.
    PubMed     Abstract available


  95. SHAO Q, Wykretowicz J, Hu N, Bedi K, et al
    Correction: Aberrant BCAT1 expression augments MTOR activity and accelerates disease progression in chronic lymphocytic leukemia.
    Leukemia. 2024 Nov 13. doi: 10.1038/s41375-024-02472.
    PubMed    


  96. TREMBLAY D, Csizmar C, DiNardo CD, Ball S, et al
    Venetoclax in combination with hypomethylating agents in chronic myelomonocytic leukemia: a propensity score matched multicenter cohort study.
    Leukemia. 2024 Nov 12. doi: 10.1038/s41375-024-02466.
    PubMed    


  97. BOUEYA IL, Sandhow L, Albuquerque JRP, Znaidi R, et al
    Endothelial heterogeneity in bone marrow: insights across development, adult life and leukemia.
    Leukemia. 2024 Nov 11. doi: 10.1038/s41375-024-02453.
    PubMed     Abstract available


  98. LI X, Zheng M, Ma S, Nie F, et al
    YTHDC1 is a therapeutic target for B-cell acute lymphoblastic leukemia by attenuating DNA damage response through the KMT2C-H3K4me1/me3 epigenetic axis.
    Leukemia. 2024 Nov 5. doi: 10.1038/s41375-024-02451.
    PubMed     Abstract available


  99. EL CHAER F, Perissinotti AJ, Loghavi S, Zeidan AM, et al
    Pre-emptive therapeutic decisions based on measurable residual disease status in acute myeloid leukemia: ready for prime time?
    Leukemia. 2024 Nov 5. doi: 10.1038/s41375-024-02458.
    PubMed     Abstract available


  100. SHAO X, Yokomori R, Ong JZL, Shen H, et al
    Transcriptional regulatory program controlled by MYB in T-cell acute lymphoblastic leukemia.
    Leukemia. 2024 Nov 2. doi: 10.1038/s41375-024-02455.
    PubMed     Abstract available


  101. INNES AJ, Hayden C, Orovboni V, Claudiani S, et al
    Impact of BCR::ABL1 single nucleotide variants on asciminib efficacy.
    Leukemia. 2024;38:2443-2455.
    PubMed     Abstract available


    October 2024
  102. SHIMONI A, Peczynski C, Labopin M, Kulagin A, et al
    Post-transplant cyclophosphamide separates graft-versus host disease and graft versus leukemia effects after HLA-matched stem-cell transplantation for acute myeloid leukemia.
    Leukemia. 2024 Oct 31. doi: 10.1038/s41375-024-02445.
    PubMed     Abstract available


  103. SAFA-TAHAR-HENNI S, Paez Martinez K, Gress V, Esparza N, et al
    Comparative small molecule screening of primary human acute leukemias, engineered human leukemia and leukemia cell lines.
    Leukemia. 2024 Oct 29. doi: 10.1038/s41375-024-02400.
    PubMed     Abstract available


  104. SHAO Q, Wykretowicz J, Hu N, Bedi K, et al
    Aberrant BCAT1 expression augments MTOR activity and accelerates disease progression in chronic lymphocytic leukemia.
    Leukemia. 2024 Oct 25. doi: 10.1038/s41375-024-02448.
    PubMed     Abstract available


  105. NARDI F, Del Prete R, Drago R, Di Rita A, et al
    Apoliprotein E-mediated ferroptosis controls cellular proliferation in chronic lymphocytic leukemia.
    Leukemia. 2024 Oct 23. doi: 10.1038/s41375-024-02442.
    PubMed     Abstract available


  106. YU M, Nah GSS, Krishnan V, Sulaimi FNB, et al
    The BIM deletion polymorphism potentiates the survival of leukemia stem and progenitor cells and impairs response to targeted therapies.
    Leukemia. 2024 Oct 22. doi: 10.1038/s41375-024-02418.
    PubMed     Abstract available


  107. YANG C, Hu Y, Gao L, Li Z, et al
    Anagrelide and idarubicin combination induces GSDME-mediated pyroptosis as a potential therapy for high-PDE3A acute myeloid leukemia.
    Leukemia. 2024 Oct 15. doi: 10.1038/s41375-024-02437.
    PubMed     Abstract available


  108. TETTERO JM, Cloos J, Bullinger L
    Acute myeloid leukemia: does sex matter?
    Leukemia. 2024 Oct 14. doi: 10.1038/s41375-024-02435.
    PubMed    


  109. YAMAMOTO Y, Iba S, Inaguma Y, Okamoto A, et al
    ELC52: a novel megakaryocytic leukemia cell line with a CALR type 1 mutation.
    Leukemia. 2024 Oct 8. doi: 10.1038/s41375-024-02434.
    PubMed    


  110. SUNAMI Y, Yoshino S, Yamazaki Y, Iwamoto T, et al
    Rapid increase of C/EBPalpha p42 induces growth arrest of acute myeloid leukemia (AML) cells by Cop1 deletion in Trib1-expressing AML.
    Leukemia. 2024 Oct 4. doi: 10.1038/s41375-024-02430.
    PubMed     Abstract available


  111. ZHANG N, Wen D, Wang T, Deng J, et al
    Disparities in incidence and mortality of pediatric acute lymphoblastic leukemia across countries with different incomes.
    Leukemia. 2024 Oct 4. doi: 10.1038/s41375-024-02433.
    PubMed    


  112. GODA C, Kulkarni R, Bustos Y, Li W, et al
    Cellular taxonomy of the preleukemic bone marrow niche of acute myeloid leukemia.
    Leukemia. 2024 Oct 2. doi: 10.1038/s41375-024-02415.
    PubMed     Abstract available


  113. KAZERANI M, Marcinek A, Philipp N, Brauchle B, et al
    Evolution of T-cell fitness through AML progression: enhanced bispecific T-cell engager-mediated function of bone marrow T cells at remission compared to initial diagnosis and relapse.
    Leukemia. 2024;38:2270-2275.
    PubMed    


  114. LEE YJ, Lee SY, Kim S, Kim SH, et al
    REXO5 promotes genomic integrity through regulating R-loop using its exonuclease activity.
    Leukemia. 2024;38:2150-2161.
    PubMed     Abstract available


  115. GALE RP, Jiang Q, Apperley JF, Hochhaus A, et al
    Is there really an accelerated phase of chronic myeloid leukaemia?
    Leukemia. 2024;38:2085-2086.
    PubMed    


    September 2024
  116. PATEL SA
    Managing the unmanageable: evidence-driven approaches to real-world patient prototypes of TP53-mutant myelodysplastic neoplasms and acute myeloid leukemia.
    Leukemia. 2024 Sep 30. doi: 10.1038/s41375-024-02417.
    PubMed     Abstract available


  117. SAKAMOTO KM
    Can PROTACs cure Leukemia?
    Leukemia. 2024 Sep 26. doi: 10.1038/s41375-024-02427.
    PubMed    


  118. RAVANDI F, Senapati J, Jain N, Short NJ, et al
    Longitudinal follow up of a phase 2 trial of venetoclax added to hyper-CVAD, nelarabine and pegylated asparaginase in patients with T-cell acute lymphoblastic leukemia and lymphoma.
    Leukemia. 2024 Sep 25. doi: 10.1038/s41375-024-02414.
    PubMed     Abstract available


  119. HUELSE JM, Bhasin SS, Jacobsen KM, Yim J, et al
    MERTK inhibition selectively activates a DC - T-cell axis to provide anti-leukemia immunity.
    Leukemia. 2024 Sep 25. doi: 10.1038/s41375-024-02408.
    PubMed     Abstract available


  120. VOLTA L, Myburgh R, Pellegrino C, Koch C, et al
    Efficient combinatorial adaptor-mediated targeting of acute myeloid leukemia with CAR T-cells.
    Leukemia. 2024 Sep 18. doi: 10.1038/s41375-024-02409.
    PubMed     Abstract available


  121. CHELYSHEVA E, Apperley J, Turkina A, Yassin MA, et al
    Correction: Chronic myeloid leukemia diagnosed in pregnancy: management and outcome of 87 patients reported to the European LeukemiaNet international registry.
    Leukemia. 2024 Sep 17. doi: 10.1038/s41375-024-02412.
    PubMed    


  122. ZHANG W, Yamamoto K, Chang YH, Yabushita T, et al
    HDAC7 is a potential therapeutic target in acute erythroid leukemia.
    Leukemia. 2024 Sep 15. doi: 10.1038/s41375-024-02394.
    PubMed     Abstract available


  123. LIU B, Zhang X, Zhou Y, Liu H, et al
    USP4 regulates ribosome biogenesis and protein synthesis for hematopoietic stem cell regeneration and leukemia progression.
    Leukemia. 2024 Sep 12. doi: 10.1038/s41375-024-02338.
    PubMed     Abstract available


  124. RABIAN F, Chevret S, Gruson B, Thepot S, et al
    Eltrombopag in chronic myelomonocytic leukemia with severe thrombocytopenia. A Groupe Francophone des Myelodysplasies (GFM) study.
    Leukemia. 2024 Sep 12. doi: 10.1038/s41375-024-02402.
    PubMed    


  125. KORBECKI J, Bosiacki M, Kupnicka P, Barczak K, et al
    CXCR4 as a therapeutic target in acute myeloid leukemia.
    Leukemia. 2024 Sep 11. doi: 10.1038/s41375-024-02326.
    PubMed     Abstract available


  126. HAGERSTRAND D, Oder B, Cortese D, Qu Y, et al
    The non-canonical BAF chromatin remodeling complex is a novel target of spliceosome dysregulation in SF3B1-mutated chronic lymphocytic leukemia.
    Leukemia. 2024 Sep 11. doi: 10.1038/s41375-024-02379.
    PubMed     Abstract available


  127. RHEINGOLD SR, Bhojwani D, Ji L, Xu X, et al
    Determinants of survival after first relapse of acute lymphoblastic leukemia: a Children's Oncology Group study.
    Leukemia. 2024 Sep 11. doi: 10.1038/s41375-024-02395.
    PubMed     Abstract available


  128. STUTTERHEIM J, van der Waarden R, de Groot-Kruseman HA, Sonneveld E, et al
    Are measurable residual disease results after consolidation therapy useful in children with acute lymphoblastic leukemia?
    Leukemia. 2024 Sep 10. doi: 10.1038/s41375-024-02386.
    PubMed     Abstract available


  129. LIU T, Xu K, Pardeshi A, Myint SS, et al
    Early-life tobacco exposure is causally implicated in aberrant RAG-mediated recombination in childhood acute lymphoblastic leukemia.
    Leukemia. 2024 Sep 9. doi: 10.1038/s41375-024-02407.
    PubMed    


  130. BOUCHER A, Murray J, Rao S
    Cohesin mutations in acute myeloid leukemia.
    Leukemia. 2024 Sep 9. doi: 10.1038/s41375-024-02406.
    PubMed     Abstract available


  131. WANG J, Jiang B, Li J, Liu L, et al
    Phase 3 study of gilteritinib versus salvage chemotherapy in predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia.
    Leukemia. 2024 Sep 5. doi: 10.1038/s41375-024-02382.
    PubMed     Abstract available


  132. VAN DER HAM CG, Suurenbroek LC, Kleisman MM, Antic Z, et al
    Mutational mechanisms in multiply relapsed pediatric acute lymphoblastic leukemia.
    Leukemia. 2024 Sep 4. doi: 10.1038/s41375-024-02403.
    PubMed     Abstract available


  133. JABBOUR E, Apperley J, Cortes J, Rea D, et al
    Correction: Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials.
    Leukemia. 2024 Sep 2. doi: 10.1038/s41375-024-02385.
    PubMed    


  134. TOMA MM, Skorski T
    Star wars against leukemia: attacking the clones.
    Leukemia. 2024 Sep 2. doi: 10.1038/s41375-024-02369.
    PubMed     Abstract available


  135. CRUZ-RODRIGUEZ N, Tang H, Bateman B, Tang W, et al
    BCR::ABL1 Proteolysis-targeting chimeras (PROTACs): The new frontier in the treatment of Ph(+) leukemias?
    Leukemia. 2024;38:1885-1893.
    PubMed     Abstract available


  136. LEYTE-VIDAL A, DeFilippis R, Outhwaite IR, Kwan I, et al
    Absence of ABL1 exon 2-encoded SH3 residues in BCR::ABL1 destabilizes the autoinhibited kinase conformation and confers resistance to asciminib.
    Leukemia. 2024;38:2046-2050.
    PubMed    


  137. PIEMONTESE S, Labopin M, Choi G, Broers AEC, et al
    Older MRD vs. younger MUD in patients older than 50 years with AML in remission using post-transplant cyclophosphamide.
    Leukemia. 2024;38:2016-2022.
    PubMed     Abstract available


  138. JANN JC, Hergott CB, Winkler M, Liu Y, et al
    Subunit-specific analysis of cohesin-mutant myeloid malignancies reveals distinct ontogeny and outcomes.
    Leukemia. 2024;38:1992-2002.
    PubMed     Abstract available


  139. WANG J, Zhang Y, Li L, Wang L, et al
    Nudt15-mediated inflammatory signaling contributes to divergent outcomes in leukemogenesis and hematopoiesis.
    Leukemia. 2024;38:1958-1970.
    PubMed     Abstract available


  140. KEWAN T, Bahaj WS, Gurnari C, Ogbue OD, et al
    Clinical and molecular characteristics of extramedullary acute myeloid leukemias.
    Leukemia. 2024;38:2032-2036.
    PubMed    


  141. AL AMRI R, Baloda V, Monaghan SA, Rosado FG, et al
    Validation of independent prognostic significance of blast count in a large cohort of MDS patients.
    Leukemia. 2024;38:2064-2067.
    PubMed    


  142. SPERK A, Gabriel A, Koch D, Augsburger A, et al
    FBXL6 is a vulnerability in AML and unmasks proteolytic cleavage as a major experimental pitfall in myeloid cells.
    Leukemia. 2024;38:2027-2031.
    PubMed    


  143. JALNAPURKAR SS, Pawar AS, George SS, Antony C, et al
    PHF6 suppresses self-renewal of leukemic stem cells in AML.
    Leukemia. 2024;38:1938-1948.
    PubMed     Abstract available


  144. MOORMAN AV, Enshaei A, Murdy D, Joy M, et al
    Integration of genetics and MRD to define low risk patients with B-cell precursor acute lymphoblastic leukaemia with intermediate MRD levels at the end of induction.
    Leukemia. 2024;38:2023-2026.
    PubMed    


  145. HERNANDEZ-SANCHEZ A, Gonzalez T, Sobas M, Strang E, et al
    Rearrangements involving 11q23.3/KMT2A in adult AML: mutational landscape and prognostic implications - a HARMONY study.
    Leukemia. 2024;38:1929-1937.
    PubMed     Abstract available


  146. LESKE IB, Hantschel O
    The e13a3 (b2a3) and e14a3 (b3a3) BCR::ABL1 isoforms are resistant to asciminib.
    Leukemia. 2024;38:2041-2045.
    PubMed    


    August 2024
  147. DERIGS P, Schubert ML, Dreger P, Schmitt A, et al
    Third-generation anti-CD19 CAR T cells for relapsed/refractory chronic lymphocytic leukemia: a phase 1/2 study.
    Leukemia. 2024 Aug 27. doi: 10.1038/s41375-024-02392.
    PubMed     Abstract available


  148. PASTORCZAK A, Urbanska Z, Styka B, Miarka-Walczyk K, et al
    Genetic hallmarks and clinical implications of chromothripsis in childhood T-cell acute lymphoblastic leukemia.
    Leukemia. 2024 Aug 27. doi: 10.1038/s41375-024-02370.
    PubMed     Abstract available


  149. DEMBITZ V, Lawson H, Burt R, Natani S, et al
    Stearoyl-CoA desaturase inhibition is toxic to acute myeloid leukemia displaying high levels of the de novo fatty acid biosynthesis and desaturation.
    Leukemia. 2024 Aug 26. doi: 10.1038/s41375-024-02390.
    PubMed     Abstract available


  150. KOEDIJK JB, van der Werf I, Penter L, Vermeulen MA, et al
    A multidimensional analysis reveals distinct immune phenotypes and the composition of immune aggregates in pediatric acute myeloid leukemia.
    Leukemia. 2024 Aug 26. doi: 10.1038/s41375-024-02381.
    PubMed     Abstract available


  151. CUGLIEVAN B, Kantarjian H, Rubnitz JE, Cooper TM, et al
    Menin inhibitors in pediatric acute leukemia: a comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the international community.
    Leukemia. 2024 Aug 23. doi: 10.1038/s41375-024-02368.
    PubMed     Abstract available


  152. SUN Y, Wu Y, Pang G, Huang J, et al
    STING is crucial for the survival of RUNX1::RUNX1T1 leukemia cells.
    Leukemia. 2024 Aug 23. doi: 10.1038/s41375-024-02383.
    PubMed     Abstract available


  153. RODRIGUEZ-ARBOLI E, Othus M, Freeman SD, Buccisano F, et al
    Optimal prognostic threshold for measurable residual disease positivity by multiparameter flow cytometry in acute myeloid leukemia (AML).
    Leukemia. 2024 Aug 21. doi: 10.1038/s41375-024-02378.
    PubMed    


  154. BOUTZEN H, Murison A, Oriecuia A, Bansal S, et al
    Identification of leukemia stem cell subsets with distinct transcriptional, epigenetic and functional properties.
    Leukemia. 2024 Aug 21. doi: 10.1038/s41375-024-02358.
    PubMed     Abstract available


  155. GAMBACORTI-PASSERINI C, Brummendorf TH, Abruzzese E, Kelly KR, et al
    Efficacy and safety of bosutinib in previously treated patients with chronic myeloid leukemia: final results from the BYOND trial.
    Leukemia. 2024 Aug 20. doi: 10.1038/s41375-024-02372.
    PubMed     Abstract available


  156. TISSINO E, Gaglio A, Nicolo A, Pozzo F, et al
    The VLA-4 integrin is constitutively active in circulating chronic lymphocytic leukemia cells via BCR autonomous signaling: a novel anchor-independent mechanism exploiting soluble blood-borne ligands.
    Leukemia. 2024 Aug 14. doi: 10.1038/s41375-024-02376.
    PubMed     Abstract available


  157. ATAR D, Ruoff L, Mast AS, Krost S, et al
    Rational combinatorial targeting by adapter CAR-T-cells (AdCAR-T) prevents antigen escape in acute myeloid leukemia.
    Leukemia. 2024 Aug 3. doi: 10.1038/s41375-024-02351.
    PubMed     Abstract available


  158. CHATAIN N, Baumeister J, Szymanski de Toledo MA, Wong DWL, et al
    Asciminib antagonizes transplantable BCR::ABL1-positive lymphoid blast crisis in vivo by targeting malignant stem cells.
    Leukemia. 2024;38:1825-1830.
    PubMed     Abstract available


  159. HOFERKOVA E, Seda V, Kadakova S, Verner J, et al
    Stromal cells engineered to express T cell factors induce robust CLL cell proliferation in vitro and in PDX co-transplantations allowing the identification of RAF inhibitors as anti-proliferative drugs.
    Leukemia. 2024;38:1699-1711.
    PubMed     Abstract available


  160. BOUSQUETS-MUNOZ P, Molina O, Varela I, Alvarez-Eguiluz A, et al
    Backtracking NOM1::ETV6 fusion to neonatal pathogenesis of t(7;12) (q36;p13) infant AML.
    Leukemia. 2024;38:1808-1812.
    PubMed    


  161. FONTANA D, Malighetti F, Villa M, Zambon A, et al
    Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1.
    Leukemia. 2024;38:1843-1847.
    PubMed    


  162. FARHAT M, Croft W, Parry HM, Verma K, et al
    PD-1 expression contributes to functional impairment of NK cells in patients with B-CLL.
    Leukemia. 2024;38:1813-1817.
    PubMed    


  163. GALE RP, Phillips GL, Lazarus HM
    A modest proposal to the transplant publik to prevent harm to people with acute myeloid leukaemia in 1st complete remission cured by chemotherapy.
    Leukemia. 2024;38:1663-1666.
    PubMed    


    July 2024
  164. WONG RL, Choi MY, Wang HY, Kipps TJ, et al
    Mutation in Bruton Tyrosine Kinase (BTK) A428D confers resistance To BTK-degrader therapy in chronic lymphocytic leukemia.
    Leukemia. 2024 Jul 24. doi: 10.1038/s41375-024-02317.
    PubMed     Abstract available


  165. KONOPLEVA M, Milella M, Ruvolo P, Watts JC, et al
    Retraction Note: MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex.
    Leukemia. 2024 Jul 18. doi: 10.1038/s41375-024-02339.
    PubMed    


  166. ORVAIN C, Bertoli S, Peterlin P, Desbrosses Y, et al
    Molecular relapse after first-line intensive therapy in patients with CBF or NPM1-mutated acute myeloid leukemia - a FILO study.
    Leukemia. 2024 Jul 17. doi: 10.1038/s41375-024-02335.
    PubMed     Abstract available


  167. TERASAKI T, Semba Y, Sasaki K, Imanaga H, et al
    The RNA helicases DDX19A/B modulate selinexor sensitivity by regulating MCL1 mRNA nuclear export in leukemia cells.
    Leukemia. 2024 Jul 11. doi: 10.1038/s41375-024-02343.
    PubMed     Abstract available


  168. EFFICACE F, Mahon FX, Richter J, Piciocchi A, et al
    Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial.
    Leukemia. 2024 Jul 10. doi: 10.1038/s41375-024-02341.
    PubMed     Abstract available


  169. OGBUE O, Kewan T, Bravo-Perez C, Unlu S, et al
    Hemolytic versus malproductive anemia in large granular lymphocytic leukemia.
    Leukemia. 2024 Jul 9. doi: 10.1038/s41375-024-02323.
    PubMed    


  170. KIM H, Tan TK, Lee DZY, Huang XZ, et al
    Oncogenic dependency on SWI/SNF chromatin remodeling factors in T-cell acute lymphoblastic leukemia.
    Leukemia. 2024 Jul 5. doi: 10.1038/s41375-024-02331.
    PubMed     Abstract available


  171. ERNST P, Rinke J, Franke GN, Dicker F, et al
    Treatment-free remission after third-line therapy with asciminib in chronic myeloid leukemia with an atypical e19a2 BCR::ABL1 transcript and T315I mutation.
    Leukemia. 2024 Jul 4. doi: 10.1038/s41375-024-02327.
    PubMed    


  172. DIEDRICH JD, Dong Q, Ferguson DC, Bergeron BP, et al
    Correction: Profiling chromatin accessibility in pediatric acute lymphoblastic leukemia identifies subtype-specific chromatin landscapes and gene regulatory networks.
    Leukemia. 2024 Jul 3. doi: 10.1038/s41375-024-02291.
    PubMed    


  173. YAMAMOTO Y, Watanabe T, Ureshino H, Kurahashi Y, et al
    DNA demethylating agents for chemoprevention of oncovirus-associated leukemogenesis.
    Leukemia. 2024;38:1613-1616.
    PubMed    


  174. SHAO Y, Kay NE, Gale RP, Liang Y, et al
    Challenges in analyzing clinical trials testing Bruton tyrosine-kinase-inhibitora in chronic lymphocytic leukaemia.
    Leukemia. 2024;38:1469-1473.
    PubMed    


  175. SCOTT S, Devonshire A, Dillon R, Thiede C, et al
    Recommendations from the AML molecular MRD expert advisory board.
    Leukemia. 2024;38:1638-1641.
    PubMed    


  176. MASLAH N, Rety S, Bonnamy M, Aguinaga L, et al
    Niclosamide combined to Azacitidine to target TP53-mutated MDS/AML cells.
    Leukemia. 2024;38:1630-1633.
    PubMed    


  177. GROSS G, Alkadieri S, Meir A, Itzhaki O, et al
    Improved CAR-T cell activity associated with increased mitochondrial function primed by galactose.
    Leukemia. 2024;38:1534-1540.
    PubMed     Abstract available


  178. SHIMONY S, Garcia JS, Keating J, Chen EC, et al
    Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients.
    Leukemia. 2024;38:1494-1500.
    PubMed     Abstract available


  179. KOVECSES O, Mercier FE, McKeague M
    Nucleic acid therapeutics as differentiation agents for myeloid leukemias.
    Leukemia. 2024;38:1441-1454.
    PubMed     Abstract available


    June 2024
  180. YUN H, Zoller J, Zhou F, Rohde C, et al
    The landscape of RNA-chromatin interaction reveals small non-coding RNAs as essential mediators of leukemia maintenance.
    Leukemia. 2024 Jun 28. doi: 10.1038/s41375-024-02322.
    PubMed     Abstract available


  181. GALE RP, Hochhaus A
    Correction: To Mars and beyond. Space exploration and space medicine in Leukemia.
    Leukemia. 2024 Jun 25. doi: 10.1038/s41375-024-02324.
    PubMed    


  182. POZZO F, Forestieri G, Vit F, Ianna G, et al
    Early reappearance of intraclonal proliferative subpopulations in ibrutinib-resistant chronic lymphocytic leukemia.
    Leukemia. 2024 Jun 24. doi: 10.1038/s41375-024-02301.
    PubMed     Abstract available


  183. YANAGIYA R, Miyatake Y, Watanabe N, Shimizu T, et al
    Amino acid influx via LAT1 regulates iron demand and sensitivity to PPMX-T003 of aggressive natural killer cell leukemia.
    Leukemia. 2024 Jun 24. doi: 10.1038/s41375-024-02296.
    PubMed     Abstract available


  184. PHILIPPE C, Jaud M, Feral K, Gay A, et al
    Pivotal role of the endoplasmic reticulum stress-related XBP1s/miR-22/SIRT1 axis in acute myeloid leukemia apoptosis and response to chemotherapy.
    Leukemia. 2024 Jun 22. doi: 10.1038/s41375-024-02321.
    PubMed     Abstract available


  185. ABOU DALLE I, Moukalled N, El Cheikh J, Mohty M, et al
    Philadelphia-chromosome positive acute lymphoblastic leukemia: ten frequently asked questions.
    Leukemia. 2024 Jun 20. doi: 10.1038/s41375-024-02319.
    PubMed     Abstract available


  186. MCCARTHY N, Gui G, Dumezy F, Roumier C, et al
    Pre-emptive detection and evolution of relapse in acute myeloid leukemia by flow cytometric measurable residual disease surveillance.
    Leukemia. 2024 Jun 18. doi: 10.1038/s41375-024-02300.
    PubMed     Abstract available


  187. MIAO H, Chen D, Ropa J, Purohit T, et al
    Combination of menin and kinase inhibitors as an effective treatment for leukemia with NUP98 translocations.
    Leukemia. 2024 Jun 18. doi: 10.1038/s41375-024-02312.
    PubMed     Abstract available


  188. SALA-TORRA O, Beppu L, Wu Q, Welch E, et al
    Point-of-care BCR::ABL1 transcript monitoring using capillary dried blood in chronic myeloid leukemia patients.
    Leukemia. 2024 Jun 15. doi: 10.1038/s41375-024-02285.
    PubMed    


  189. GREVER M, Andritsos L, Anghelina M, Arons E, et al
    Hairy cell leukemia variant and WHO classification correspondence Re: 5(th) edition WHO classification haematolymphoid tumors: lymphoid neoplasms.
    Leukemia. 2024 Jun 8. doi: 10.1038/s41375-024-02280.
    PubMed    


  190. OSTERGAARD A, Fiocco M, de Groot-Kruseman H, Moorman AV, et al
    ETV6::RUNX1 Acute Lymphoblastic Leukemia: how much therapy is needed for cure?
    Leukemia. 2024 Jun 6. doi: 10.1038/s41375-024-02287.
    PubMed     Abstract available


  191. ZHANG MY, Othus M, McMillen K, Erba HP, et al
    Association between class III obesity and overall survival in previously untreated younger patients with acute myeloid leukemia enrolled on SWOG S1203.
    Leukemia. 2024 Jun 3. doi: 10.1038/s41375-024-02288.
    PubMed     Abstract available


  192. VAN DER VELDEN VHJ, Dombrink I, Alten J, Cazzaniga G, et al
    Analysis of measurable residual disease by IG/TR gene rearrangements: quality assurance and updated EuroMRD guidelines.
    Leukemia. 2024;38:1315-1322.
    PubMed     Abstract available


  193. SAYITOGLU EC, Luca BA, Boss AP, Thomas BC, et al
    AML/T cell interactomics uncover correlates of patient outcomes and the key role of ICAM1 in T cell killing of AML.
    Leukemia. 2024;38:1246-1255.
    PubMed     Abstract available


  194. YANG M, Ma Z, Wang C, Agca MC, et al
    Cre recombinase promotes leukemogenesis in the presence of both homozygous and heterozygous FLT3-ITD.
    Leukemia. 2024;38:1437-1439.
    PubMed    


  195. LU W, Lyu H, Xiao X, Bai X, et al
    Prophylactic donor-derived CD19 CAR-T cell infusion for preventing relapse in high-risk B-ALL after allogeneic hematopoietic stem cell transplantation.
    Leukemia. 2024;38:1419-1422.
    PubMed    


  196. VAN SPRONSEN MF, Van Gassen S, Duetz C, Westers TM, et al
    Myelodysplastic neoplasms dissected into indolent, leukaemic and unfavourable subtypes by computational clustering of haematopoietic stem and progenitor cells.
    Leukemia. 2024;38:1365-1377.
    PubMed     Abstract available


  197. PERZOLLI A, Koedijk JB, Zwaan CM, Heidenreich O, et al
    Targeting the innate immune system in pediatric and adult AML.
    Leukemia. 2024;38:1191-1201.
    PubMed     Abstract available


    May 2024
  198. ZHU R, Shirley CM, Chu SH, Li L, et al
    Inhibition of NOTCH4 sensitizes FLT3/ITD acute myeloid leukemia cells to FLT3 tyrosine kinase inhibition.
    Leukemia. 2024 May 29. doi: 10.1038/s41375-024-02292.
    PubMed     Abstract available


  199. GALE RP, Hochhaus A
    To Mars and beyond. Space exploration and space medicine in Leukemia.
    Leukemia. 2024 May 22. doi: 10.1038/s41375-024-02286.
    PubMed    


  200. RUJKIJYANONT P, Inaba H
    Diagnostic and treatment strategies for pediatric acute lymphoblastic leukemia in low- and middle-income countries.
    Leukemia. 2024 May 18. doi: 10.1038/s41375-024-02277.
    PubMed     Abstract available


  201. CORTES JE, Sasaki K, Kim DW, Hughes TP, et al
    Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after >/=1 prior tyrosine kinase inhibitor: 2-year follow-up results.
    Leukemia. 2024 May 16. doi: 10.1038/s41375-024-02278.
    PubMed     Abstract available


  202. MALCIKOVA J, Pavlova S, Baliakas P, Chatzikonstantinou T, et al
    ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-2024 update.
    Leukemia. 2024 May 16. doi: 10.1038/s41375-024-02267.
    PubMed     Abstract available


  203. NEUMANN M, Beder T, Bastian L, Hanzelmann S, et al
    Molecular subgroups of T-cell acute lymphoblastic leukemia in adults treated according to pediatric-based GMALL protocols.
    Leukemia. 2024 May 14. doi: 10.1038/s41375-024-02264.
    PubMed     Abstract available


  204. KARAMI A, Skorski T
    DNA damage response genes as biomarkers of therapeutic outcomes in acute myeloid leukemia patients.
    Leukemia. 2024 May 11. doi: 10.1038/s41375-024-02269.
    PubMed    


  205. AWADA H, Durmaz A, Kewan T, Ullah F, et al
    Context-dependent role of trisomy 6 in myelodysplastic neoplasms and acute myeloid leukemia: a multi-omics analysis.
    Leukemia. 2024 May 11. doi: 10.1038/s41375-024-02268.
    PubMed    


  206. MORII M, Kubota S, Iimori M, Yokomizo-Nakano T, et al
    TIF1beta activates leukemic transcriptional program in HSCs and promotes BCR::ABL1-induced myeloid leukemia.
    Leukemia. 2024 May 11. doi: 10.1038/s41375-024-02276.
    PubMed     Abstract available


  207. O'CONNOR KW, Kishimoto K, Kuzma IO, Wagner KP, et al
    The role of quiescent thymic progenitors in TAL/LMO2-induced T-ALL chemotolerance.
    Leukemia. 2024;38:951-962.
    PubMed     Abstract available


  208. SRINIVASAN S, Keerthivasagam S
    Mitigating immortal-time bias: exploring osteonecrosis and survival in pediatric ALL - AALL0232 trial insights.
    Leukemia. 2024;38:1187-1188.
    PubMed    


  209. SCHULTZ LM, Jeyakumar N, Kramer AM, Sahaf B, et al
    CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results.
    Leukemia. 2024;38:963-968.
    PubMed     Abstract available


  210. WONG JC, Weinfurtner KM, Westover T, Kim J, et al
    5G2 mutant mice model loss of a commonly deleted segment of chromosome 7q22 in myeloid malignancies.
    Leukemia. 2024;38:1182-1186.
    PubMed     Abstract available


  211. YI W, Zhang J, Huang Y, Zhan Q, et al
    Ferritin-mediated mitochondrial iron homeostasis is essential for the survival of hematopoietic stem cells and leukemic stem cells.
    Leukemia. 2024;38:1003-1018.
    PubMed     Abstract available


    April 2024
  212. GUO J, Buettner R, Du L, Li Z, et al
    8-Cl-Ado and 8-NH(2)-Ado synergize with venetoclax to target the methionine-MAT2A-SAM axis in acute myeloid leukemia.
    Leukemia. 2024 Apr 20. doi: 10.1038/s41375-024-02222.
    PubMed     Abstract available


  213. IYODA S, Yoshida K, Shoji K, Ito N, et al
    KRAS G12 mutations as adverse prognostic factors in KMT2A-rearranged acute myeloid leukemia.
    Leukemia. 2024 Apr 18. doi: 10.1038/s41375-024-02244.
    PubMed    


  214. NORONHA N, Durette C, Cahuzac M, E Silva B, et al
    Autophagy degrades immunogenic endogenous retroelements induced by 5-azacytidine in acute myeloid leukemia.
    Leukemia. 2024 Apr 16. doi: 10.1038/s41375-024-02250.
    PubMed     Abstract available


  215. CURIK N, Laznicka A, Polivkova V, Krizkova J, et al
    Combination therapies with ponatinib and asciminib in a preclinical model of chronic myeloid leukemia blast crisis with compound mutations.
    Leukemia. 2024 Apr 13. doi: 10.1038/s41375-024-02248.
    PubMed    


  216. MATSUI S, Ri C, Bolanos LC, Choi K, et al
    Metabolic reprogramming regulated by TRAF6 contributes to the leukemia progression.
    Leukemia. 2024 Apr 12. doi: 10.1038/s41375-024-02245.
    PubMed     Abstract available


  217. BELL HL, Blair HJ, Jepson Gosling SJ, Galler M, et al
    Combination p53 activation and BCL-x(L)/BCL-2 inhibition as a therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia.
    Leukemia. 2024 Apr 10. doi: 10.1038/s41375-024-02241.
    PubMed     Abstract available


  218. FRUCHTMAN H, Avigan ZM, Waksal JA, Brennan N, et al
    Management of isocitrate dehydrogenase 1/2 mutated acute myeloid leukemia.
    Leukemia. 2024 Apr 10. doi: 10.1038/s41375-024-02246.
    PubMed     Abstract available


  219. BORDINI J, Lenzi C, Frenquelli M, Morabito A, et al
    IkappaBepsilon deficiency accelerates disease development in chronic lymphocytic leukemia.
    Leukemia. 2024 Apr 4. doi: 10.1038/s41375-024-02236.
    PubMed     Abstract available


  220. MCLORNAN DP, Czerw T, Damaj G, Ethell M, et al
    Allogeneic haematopoietic cell transplantation for advanced systemic mastocytosis: Best practice recommendations on behalf of the EBMT Practice Harmonisation and Guidelines Committee.
    Leukemia. 2024;38:699-711.
    PubMed     Abstract available


  221. LUBKE J, Christen D, Schwaab J, Kaiser A, et al
    Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis: A retrospective analysis of the DRST and GREM registries.
    Leukemia. 2024;38:810-821.
    PubMed     Abstract available


  222. SHIMONY S, Bewersdorf JP, Shallis RM, Liu Y, et al
    Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML.
    Leukemia. 2024;38:762-768.
    PubMed     Abstract available


  223. SEBERT M, Freiman L, Chaffaut C, Guerci A, et al
    Clinical impact of genetic alterations including germline DDX41 mutations in MDS/low-blast count AML patients treated with azacitidine-based regimens.
    Leukemia. 2024;38:918-922.
    PubMed    


  224. SEVERENS JF, Karakaslar EO, van der Reijden BA, Sanchez-Lopez E, et al
    Mapping AML heterogeneity - multi-cohort transcriptomic analysis identifies novel clusters and divergent ex-vivo drug responses.
    Leukemia. 2024;38:751-761.
    PubMed     Abstract available


    March 2024
  225. JASSINSKAJA M, Ghosh S, Watral J, Davoudi M, et al
    A complex interplay of intra- and extracellular factors regulates the outcome of fetal- and adult-derived MLL-rearranged leukemia.
    Leukemia. 2024 Mar 30. doi: 10.1038/s41375-024-02235.
    PubMed     Abstract available


  226. BRIOLI A, Lomaia E, Fabisch C, Sacha T, et al
    Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry.
    Leukemia. 2024 Mar 28. doi: 10.1038/s41375-024-02204.
    PubMed     Abstract available


  227. DE CAMARGO MAGALHAES ES, Hubner SE, Brown BD, Qiu Y, et al
    Proteomics for optimizing therapy in acute myeloid leukemia: venetoclax plus hypomethylating agents versus conventional chemotherapy.
    Leukemia. 2024 Mar 26. doi: 10.1038/s41375-024-02208.
    PubMed     Abstract available


  228. KANTARJIAN H, Branford S, Breccia M, Cortes J, et al
    Are there new relevant therapeutic endpoints in the modern era of the BCR::ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia?
    Leukemia. 2024 Mar 26. doi: 10.1038/s41375-024-02229.
    PubMed    


  229. BURMEISTER T, Stroh AS, Kehden B, Trautmann H, et al
    Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia.
    Leukemia. 2024 Mar 22. doi: 10.1038/s41375-024-02209.
    PubMed    


  230. FARROKHI A, Atre T, Rever J, Fidanza M, et al
    The Emu-Ret mouse is a novel model of hyperdiploid B-cell acute lymphoblastic leukemia.
    Leukemia. 2024 Mar 22. doi: 10.1038/s41375-024-02221.
    PubMed     Abstract available


  231. BONATO A, Chakraborty S, Bomben R, Canarutto G, et al
    NFKBIE mutations are selected by the tumor microenvironment and contribute to immune escape in chronic lymphocytic leukemia.
    Leukemia. 2024 Mar 15. doi: 10.1038/s41375-024-02224.
    PubMed     Abstract available


  232. ZACKOVA D, Semerad L, Faber E, Klamova H, et al
    Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF.
    Leukemia. 2024 Mar 12. doi: 10.1038/s41375-024-02215.
    PubMed    


  233. SCHWEDE M, Jahn K, Kuipers J, Miles LA, et al
    Mutation order in acute myeloid leukemia identifies uncommon patterns of evolution and illuminates phenotypic heterogeneity.
    Leukemia. 2024 Mar 11. doi: 10.1038/s41375-024-02211.
    PubMed     Abstract available


  234. AKIYAMA H, Zhao R, Ostermann LB, Li Z, et al
    Correction: Mitochondrial regulation of GPX4 inhibition-mediated ferroptosis in acute myeloid leukemia.
    Leukemia. 2024 Mar 8. doi: 10.1038/s41375-024-02202.
    PubMed    


  235. THOMAS ME 3RD, Qi W, Walsh MP, Ma J, et al
    Functional characterization of cooperating MGA mutations in RUNX1::RUNX1T1 acute myeloid leukemia.
    Leukemia. 2024 Mar 7. doi: 10.1038/s41375-024-02193.
    PubMed     Abstract available


  236. PERUSINI MA, Andrews C, Eshetu AG, Gupta V, et al
    Asparaginase completion among adults including older patients with acute lymphoblastic leukemia treated with a modified DFCI protocol.
    Leukemia. 2024 Mar 2. doi: 10.1038/s41375-024-02201.
    PubMed    


  237. MA J, Liu YC, Voss RK, Ma J, et al
    Genomic and global gene expression profiling in pediatric and young adult acute leukemia with PICALM::MLLT10 Fusion.
    Leukemia. 2024 Mar 1. doi: 10.1038/s41375-024-02194.
    PubMed     Abstract available


  238. CHEN CC, Silberman RE, Ma D, Perry JA, et al
    Inherent genome instability underlies trisomy 21-associated myeloid malignancies.
    Leukemia. 2024;38:521-529.
    PubMed     Abstract available


  239. SANZ-ORTEGA L, Andersson A, Carlsten M
    Harnessing upregulated E-selectin while enhancing SDF-1alpha sensing redirects infused NK cells to the AML-perturbed bone marrow.
    Leukemia. 2024;38:579-589.
    PubMed     Abstract available


  240. PARRIOTT G, Hegermiller E, Morman RE, Frank C, et al
    Loss of thymocyte competition underlies the tumor suppressive functions of the E2a transcription factor in T-ALL.
    Leukemia. 2024;38:491-501.
    PubMed     Abstract available


  241. SPINELLA JF, Chagraoui J, Moison C, Lavallee VP, et al
    DELE1 haploinsufficiency causes resistance to mitochondrial stress-induced apoptosis in monosomy 5/del(5q) AML.
    Leukemia. 2024;38:530-537.
    PubMed     Abstract available


  242. BIRDWELL CE, Fiskus W, Kadia TM, Mill CP, et al
    Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression.
    Leukemia. 2024;38:545-556.
    PubMed     Abstract available


    February 2024
  243. CLAUDIANI S, Chughtai F, Khan A, Hayden C, et al
    Long-term outcomes after upfront second-generation tyrosine kinase inhibitors for chronic myeloid leukemia: managing intolerance and resistance.
    Leukemia. 2024 Feb 29. doi: 10.1038/s41375-024-02187.
    PubMed     Abstract available


  244. YANG X, Liu J, Liu W, Wu H, et al
    circFAM193B interaction with PRMT6 regulates AML leukemia stem cells chemoresistance through altering the oxidative metabolism and lipid peroxidation.
    Leukemia. 2024 Feb 29. doi: 10.1038/s41375-024-02189.
    PubMed     Abstract available


  245. FLYGT H, Soderlund S, Richter J, Saussele S, et al
    Correction: Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial.
    Leukemia. 2024 Feb 28. doi: 10.1038/s41375-024-02184.
    PubMed    


  246. MONTALBAN-BRAVO G, Rodriguez-Sevilla JJ, Swanson DM, Kanagal-Shamanna R, et al
    Influence of co-mutational patterns in disease phenotype and clinical outcomes of chronic myelomonocytic leukemia.
    Leukemia. 2024 Feb 28. doi: 10.1038/s41375-024-02190.
    PubMed    


  247. JUNK SV, Forster A, Schmidt G, Zimmermann M, et al
    Germline variants in patients developing second malignant neoplasms after therapy for pediatric acute lymphoblastic leukemia-a case-control study.
    Leukemia. 2024 Feb 27. doi: 10.1038/s41375-024-02173.
    PubMed    


  248. CHELYSHEVA E, Apperley J, Turkina A, Yassin MA, et al
    Chronic myeloid leukemia diagnosed in pregnancy: management and outcome of 87 patients reported to the European LeukemiaNet international registry.
    Leukemia. 2024 Feb 23. doi: 10.1038/s41375-024-02183.
    PubMed     Abstract available


  249. OLIVIERI DJ, Othus M, Orvain C, Rodriguez-Arboli E, et al
    Impact of socioeconomic disparities on outcomes in adults undergoing allogeneic hematopoietic cell transplantation for acute myeloid leukemia.
    Leukemia. 2024 Feb 22. doi: 10.1038/s41375-024-02172.
    PubMed     Abstract available


  250. AVENARIUS MR, Huang Y, Kittai AS, Bhat SA, et al
    Comparison of karyotype scoring guidelines for evaluating karyotype complexity in chronic lymphocytic leukemia.
    Leukemia. 2024 Feb 19. doi: 10.1038/s41375-024-02177.
    PubMed    


  251. CHATZIKONSTANTINOU T, Agathangelidis A, Chatzidimitriou A, Tresoldi C, et al
    Updates of the ERIC recommendations on how to report the results from immunoglobulin heavy variable gene analysis in chronic lymphocytic leukemia.
    Leukemia. 2024 Feb 16. doi: 10.1038/s41375-024-02163.
    PubMed    


  252. LIN S, Schneider C, Su AH, Alexe G, et al
    The UBE2J2/UBE2K-MARCH5 ubiquitination machinery regulates apoptosis in response to venetoclax in acute myeloid leukemia.
    Leukemia. 2024 Feb 16. doi: 10.1038/s41375-024-02178.
    PubMed    


  253. DELROCCO NJ, Loh ML, Borowitz MJ, Gupta S, et al
    Enhanced Risk Stratification for Children and Young Adults with B-Cell Acute Lymphoblastic Leukemia: A Children's Oncology Group Report.
    Leukemia. 2024 Feb 15. doi: 10.1038/s41375-024-02166.
    PubMed     Abstract available


  254. LI Y, Mendoza-Castrejon J, Patel RM, Casey EB, et al
    LIN28B promotes differentiation of fully transformed AML cells but is dispensable for fetal leukemia suppression.
    Leukemia. 2024 Feb 6. doi: 10.1038/s41375-024-02167.
    PubMed    


  255. FRANKHOUSER DE, Rockne RC, Uechi L, Zhao D, et al
    State-transition modeling of blood transcriptome predicts disease evolution and treatment response in chronic myeloid leukemia.
    Leukemia. 2024 Feb 2. doi: 10.1038/s41375-024-02142.
    PubMed     Abstract available


  256. KLYUCHNIKOV E, Badbaran A, Massoud R, Freiberger P, et al
    Peri-transplant flow-MRD assessment of cells with leukemic stem cells (LSC) associated phenotype in AML patients undergoing allogeneic stem cell transplantation in CR.
    Leukemia. 2024;38:386-388.
    PubMed    


  257. ELDEEB M, Konturek-Ciesla A, Zhang Q, Kharazi S, et al
    Ontogeny shapes the ability of ETV6::RUNX1 to enhance hematopoietic stem cell self-renewal and disrupt early lymphopoiesis.
    Leukemia. 2024;38:455-459.
    PubMed    


  258. GEORGI JA, Stasik S, Kramer M, Meggendorfer M, et al
    Prognostic impact of CEBPA mutational subgroups in adult AML.
    Leukemia. 2024;38:281-290.
    PubMed     Abstract available


  259. HEHLMANN R, Lauseker M
    How to individualize therapy after failing milestones in chronic myeloid leukaemia: weighting late response and early death from CML against risk of alternative therapies.
    Leukemia. 2024;38:465-466.
    PubMed    


  260. CHEN J, Gale RP
    Response to Pfirrmann et al.'s comment on How should we interpret conclusions of TKI-stopping studies.
    Leukemia. 2024;38:463-464.
    PubMed    


  261. LEE KH, Lee S, Park YH, Mun YC, et al
    Interleukin-15 and -21-activated, donor-derived NK cell infusion after haploidentical HCT in high-risk AML and MDS-a cohort analysis.
    Leukemia. 2024;38:451-454.
    PubMed    


  262. MATTANO LA JR, Devidas M, Loh ML, Raetz EA, et al
    Development of osteonecrosis and improved survival in B-ALL: results of Children's Oncology Group Trial AALL0232.
    Leukemia. 2024;38:258-265.
    PubMed     Abstract available


  263. CHEN Y, Wen J, Li Q, Peng D, et al
    RAB27B-regulated exosomes mediate LSC maintenance via resistance to senescence and crosstalk with the microenvironment.
    Leukemia. 2024;38:266-280.
    PubMed     Abstract available


  264. SUI P, Ge G, Chen S, Bai J, et al
    SRSF2 mutation cooperates with ASXL1 truncated alteration to accelerate leukemogenesis.
    Leukemia. 2024;38:408-411.
    PubMed    


    January 2024
  265. DAM M, Centanni M, Friberg LE, Centanni D, et al
    Increase in peg-asparaginase clearance as a predictor for inactivation in patients with acute lymphoblastic leukemia.
    Leukemia. 2024 Jan 29. doi: 10.1038/s41375-024-02153.
    PubMed     Abstract available


  266. JABBOUR E, Apperley J, Cortes J, Rea D, et al
    Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials.
    Leukemia. 2024 Jan 29. doi: 10.1038/s41375-024-02159.
    PubMed     Abstract available


  267. FLYGT H, Soderlund S, Richter J, Saussele S, et al
    Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial.
    Leukemia. 2024 Jan 26. doi: 10.1038/s41375-024-02145.
    PubMed     Abstract available


  268. TAN SH, Tan TK, Yokomori R, Liao M, et al
    Correction to: TAL1 hijacks MYCN enhancer that induces MYCN expression and dependence on mevalonate pathway in T-cell acute lymphoblastic leukemia.
    Leukemia. 2024 Jan 25. doi: 10.1038/s41375-023-02125.
    PubMed    


  269. TETTERO JM, Heidinga ME, Mocking TR, Fransen G, et al
    Impact of hemodilution on flow cytometry based measurable residual disease assessment in acute myeloid leukemia.
    Leukemia. 2024 Jan 25. doi: 10.1038/s41375-024-02158.
    PubMed     Abstract available


  270. APPELBAUM JS, Wei AH, Mandrekar SJ, Tiong IS, et al
    Clinical evaluation of complete remission (CR) with partial hematologic recovery (CRh) in acute myeloid leukemia: a report of 7235 patients from seven cohorts.
    Leukemia. 2024 Jan 23. doi: 10.1038/s41375-024-02143.
    PubMed    


  271. KANG H, Hoang DH, Valerio M, Pathak K, et al
    OST-01, a natural product from Baccharis coridifolia, targets c-Myc-dependent ribogenesis in acute myeloid leukemia.
    Leukemia. 2024 Jan 17. doi: 10.1038/s41375-024-02146.
    PubMed    


  272. TOMA MM, Karami A, Nieborowska-Skorska M, Chirtala KN, et al
    Clonal medicine targeting DNA damage response eradicates leukemia.
    Leukemia. 2024 Jan 16. doi: 10.1038/s41375-024-02138.
    PubMed    


  273. CHEN DW, Fan JM, Schrey JM, Mitchell DV, et al
    Inflammatory recruitment of healthy hematopoietic stem and progenitor cells in the acute myeloid leukemia niche.
    Leukemia. 2024 Jan 16. doi: 10.1038/s41375-024-02136.
    PubMed     Abstract available


  274. HANEL G, Schonle A, Neumann AS, Nixdorf D, et al
    Combining venetoclax and azacytidine with T-cell bispecific antibodies for treatment of acute myeloid leukemia: a preclinical assessment.
    Leukemia. 2024 Jan 11. doi: 10.1038/s41375-023-02127.
    PubMed    


  275. VALTIS YK, Flamand Y, Shimony S, Place AE, et al
    Treatment completion, asparaginase completion, and oncologic outcomes among children, adolescents and young adults with acute lymphoblastic leukemia treated with DFCI Consortium Protocols.
    Leukemia. 2024 Jan 5. doi: 10.1038/s41375-023-02115.
    PubMed     Abstract available


  276. SUNG PJ, Selvam M, Riedel SS, Xie HM, et al
    FLT3 tyrosine kinase inhibition modulates PRC2 and promotes differentiation in acute myeloid leukemia.
    Leukemia. 2024 Jan 5. doi: 10.1038/s41375-023-02131.
    PubMed     Abstract available


  277. POTLURI S, Kellaway SG, Coleman DJL, Keane P, et al
    Gene regulation in t(6;9) DEK::NUP214 Acute Myeloid Leukemia resembles that of FLT3-ITD/NPM1 Acute Myeloid Leukemia but with an altered HOX/MEIS axis.
    Leukemia. 2024 Jan 4. doi: 10.1038/s41375-023-02118.
    PubMed    


  278. MORLEY AA
    Quantifying measurable residual disease correctly.
    Leukemia. 2024;38:221-222.
    PubMed    


  279. TYAGI A, Jaggupilli A, Ly S, Yuan B, et al
    TP-0184 inhibits FLT3/ACVR1 to overcome FLT3 inhibitor resistance and hinder AML growth synergistically with venetoclax.
    Leukemia. 2024;38:82-95.
    PubMed     Abstract available


  280. ZHOU YL, Zhao MY, Gale RP, Jiang H, et al
    Mutations in DEAD/H-box helicase 11 correlate with increased relapse risk in adults with acute myeloid leukaemia with normal cytogenetics.
    Leukemia. 2024;38:223-225.
    PubMed    


  281. CHEN J
    Response to comment on Have we been qualifying measurable residual disease correctly?
    Leukemia. 2024;38:219-220.
    PubMed    


  282. RADIVOYEVITCH T, Gale RP, Kalaycio ME
    What do atomic bomb survivors teach us about therapy-free remission in people with chronic myeloid leukaemia?
    Leukemia. 2024;38:207-209.
    PubMed    


  283. GARCIA-MANERO G, Podoltsev NA, Othus M, Pagel JM, et al
    A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML.
    Leukemia. 2024;38:58-66.
    PubMed     Abstract available


  284. YAN M, Liu M, Davis AG, Stoner SA, et al
    Single-cell RNA sequencing of a new transgenic t(8;21) preleukemia mouse model reveals regulatory networks promoting leukemic transformation.
    Leukemia. 2024;38:31-44.
    PubMed     Abstract available


    December 2023
  285. AKIYAMA H, Zhao R, Ostermann LB, Li Z, et al
    Mitochondrial regulation of GPX4 inhibition-mediated ferroptosis in acute myeloid leukemia.
    Leukemia. 2023 Dec 26. doi: 10.1038/s41375-023-02117.
    PubMed     Abstract available


  286. YANADA M, Yamasaki S, Kondo T, Kawata T, et al
    Allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia not in remission.
    Leukemia. 2023 Dec 21. doi: 10.1038/s41375-023-02119.
    PubMed     Abstract available


  287. MACHOVA POLAKOVA K, Albeer A, Polivkova V, Krutska M, et al
    The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib.
    Leukemia. 2023 Dec 21. doi: 10.1038/s41375-023-02109.
    PubMed     Abstract available


  288. DE SMITH AJ, Wiemels JL, Mead AJ, Roberts I, et al
    Backtracking to the future: unraveling the origins of childhood leukemia.
    Leukemia. 2023 Dec 20. doi: 10.1038/s41375-023-02111.
    PubMed    


  289. FIJALKOWSKI I, Wang J, Jin Q, Van Laere J, et al
    Correction: A positive feedback loop regulation between NOTCH1 and USP11 in T-cell leukemia.
    Leukemia. 2023 Dec 19. doi: 10.1038/s41375-023-02112.
    PubMed    


  290. MURPHY T, Mason JM, Leber B, Bray MR, et al
    Preclinical characterization and clinical trial of CFI-400945, a polo-like kinase 4 inhibitor, in patients with relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic neoplasms.
    Leukemia. 2023 Dec 19. doi: 10.1038/s41375-023-02110.
    PubMed     Abstract available


  291. HOFFMEISTER LM, Suttorp J, Walter C, Antoniou E, et al
    Panel-based RNA fusion sequencing improves diagnostics of pediatric acute myeloid leukemia.
    Leukemia. 2023 Dec 12. doi: 10.1038/s41375-023-02102.
    PubMed     Abstract available


  292. KOVTUN I, von Bonin M, Ibneeva L, Frimmel J, et al
    Profound sympathetic neuropathy in the bone marrow of patients with acute myeloid leukemia.
    Leukemia. 2023 Dec 8. doi: 10.1038/s41375-023-02104.
    PubMed    


  293. TANNOURY M, Ayoub M, Dehgane L, Nemazanyy I, et al
    ACOX1-mediated peroxisomal fatty acid oxidation contributes to metabolic reprogramming and survival in chronic lymphocytic leukemia.
    Leukemia. 2023 Dec 6. doi: 10.1038/s41375-023-02103.
    PubMed     Abstract available


  294. SABA L, Landau KS, Liang H, Fu CL, et al
    Real world analysis on the determinants of survival in primary plasma cell leukemia in the United States.
    Leukemia. 2023 Dec 4. doi: 10.1038/s41375-023-02100.
    PubMed    


  295. ANTIC Z, van Bommel A, Riege K, Lentes J, et al
    Recurrent DNMT3B rearrangements are associated with unfavorable outcome in dicentric (9;20)-positive pediatric BCP-ALL.
    Leukemia. 2023;37:2522-2525.
    PubMed    


  296. SCHIFFER CA
    Glasdigib fails to slay the hedgehog in pivotal AML trials.
    Leukemia. 2023;37:2520-2521.
    PubMed    


  297. BOUCHLA A, Papageorgiou SG, Symeonidis A, Sakellari I, et al
    Evaluation of complete response to azacitidine according to the revised International Working Group 2023 response criteria for higher risk MDS. Does it make a difference in patients' outcome?
    Leukemia. 2023;37:2517-2519.
    PubMed    


  298. XIANG J, Devenport JM, Carter AJ, Staser KW, et al
    An "off-the-shelf" CD2 universal CAR-T therapy for T-cell malignancies.
    Leukemia. 2023;37:2448-2456.
    PubMed     Abstract available


    November 2023
  299. MILIARA S, Cozzi E, Zhong X, Chan I, et al
    The exon-junction complex helicase eIF4A3 holds therapeutic potential in acute myeloid leukemia.
    Leukemia. 2023 Nov 30. doi: 10.1038/s41375-023-02098.
    PubMed    


  300. PLAYA-ALBINYANA H, Arenas F, Royo R, Giro A, et al
    Chronic lymphocytic leukemia patient-derived xenografts recapitulate clonal evolution to Richter transformation.
    Leukemia. 2023 Nov 28. doi: 10.1038/s41375-023-02095.
    PubMed     Abstract available


  301. OZGA M, Nicolet D, Mrozek K, Yilmaz AS, et al
    Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG).
    Leukemia. 2023 Nov 28. doi: 10.1038/s41375-023-02068.
    PubMed     Abstract available


  302. ROSTI G, Brummendorf TH, Gjertsen BT, Giraldo-Castellano P, et al
    Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia: results from the phase 4 BYOND study.
    Leukemia. 2023 Nov 25. doi: 10.1038/s41375-023-02080.
    PubMed     Abstract available


  303. FIJALKOWSKI I, Wang J, Jin Q, Van Laere J, et al
    A positive feedback loop regulation between NOTCH1 and USP11 in T-cell leukemia.
    Leukemia. 2023 Nov 25. doi: 10.1038/s41375-023-02096.
    PubMed    


  304. LEUNG KT, Cai J, Liu Y, Chan KYY, et al
    Prognostic implications of CD9 in childhood acute lymphoblastic leukemia: insights from a nationwide multicenter study in China.
    Leukemia. 2023 Nov 25. doi: 10.1038/s41375-023-02089.
    PubMed     Abstract available


  305. ZALIOVA M, Zuna J, Winkowska L, Janotova I, et al
    Genomic DNA-based measurable residual disease monitoring in pediatric acute myeloid leukemia: unselected consecutive cohort study.
    Leukemia. 2023 Nov 24. doi: 10.1038/s41375-023-02083.
    PubMed     Abstract available


  306. WALTER RB
    Perspective on measurable residual disease testing in acute myeloid leukemia.
    Leukemia. 2023 Nov 16. doi: 10.1038/s41375-023-02084.
    PubMed    


  307. WU Y, Zehnle PMA, Rajak J, Koleci N, et al
    BH3 mimetics and azacitidine show synergistic effects on juvenile myelomonocytic leukemia.
    Leukemia. 2023 Nov 9. doi: 10.1038/s41375-023-02079.
    PubMed     Abstract available


  308. ALSHAMLEH I, Kurrle N, Makowka P, Bhayadia R, et al
    PDP1 is a key metabolic gatekeeper and modulator of drug resistance in FLT3-ITD-positive acute myeloid leukemia.
    Leukemia. 2023 Nov 7. doi: 10.1038/s41375-023-02041.
    PubMed     Abstract available


  309. TOMIZAWA D, Matsubayashi J, Iwamoto S, Hiramatsu H, et al
    High-dose cytarabine induction therapy and flow cytometric measurable residual disease monitoring for children with acute myeloid leukemia.
    Leukemia. 2023 Nov 6. doi: 10.1038/s41375-023-02075.
    PubMed    


  310. HUUHTANEN J, Adnan-Awad S, Theodoropoulos J, Forsten S, et al
    Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation.
    Leukemia. 2023 Nov 2. doi: 10.1038/s41375-023-02074.
    PubMed     Abstract available


  311. WEISCHENDORFF S, Rathe M, Petersen MJ, Weimann A, et al
    Markers of intestinal mucositis to predict blood stream infections at the onset of fever during treatment for childhood acute leukemia.
    Leukemia. 2023 Nov 2. doi: 10.1038/s41375-023-02077.
    PubMed     Abstract available


  312. FALINI B, Gjertsen BT, Andresen V
    The acidic stretch and the C-terminal nuclear export signal motif of NPM1 mutant: are they druggable in AML?
    Leukemia. 2023;37:2173-2175.
    PubMed    


  313. LAUSEKER M, Hehlmann R, Hochhaus A, Saussele S, et al
    Survival with chronic myeloid leukaemia after failing milestones.
    Leukemia. 2023;37:2231-2236.
    PubMed     Abstract available


  314. DU W, Xia Z, Luo Z, Chen Y, et al
    A novel gene fusion RUNX1/ZNF423 promotes leukemic relapse of NUP98-rearranged AML.
    Leukemia. 2023;37:2286-2291.
    PubMed    


  315. BUROCZIOVA M, Danek P, Oravetzova A, Chalupova Z, et al
    Ppm1d truncating mutations promote the development of genotoxic stress-induced AML.
    Leukemia. 2023;37:2209-2220.
    PubMed     Abstract available


  316. FENG Y, Qi S, Liu X, Zhang L, et al
    Have we been qualifying measurable residual disease correctly?
    Leukemia. 2023;37:2168-2172.
    PubMed    


  317. LI S, Wang X, Liu L, Liu J, et al
    CD7 targeted "off-the-shelf" CAR-T demonstrates robust in vivo expansion and high efficacy in the treatment of patients with relapsed and refractory T cell malignancies.
    Leukemia. 2023;37:2176-2186.
    PubMed     Abstract available


    October 2023
  318. CERELLA C, Gajulapalli SR, Lorant A, Gerard D, et al
    ATP1A1/BCL2L1 predicts the response of myelomonocytic and monocytic acute myeloid leukemia to cardiac glycosides.
    Leukemia. 2023 Oct 30. doi: 10.1038/s41375-023-02076.
    PubMed     Abstract available


  319. BISCHOF L, Ussmann J, Grimm J, Bill M, et al
    Prognostic impact of measurable residual clonal hematopoiesis in acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation.
    Leukemia. 2023 Oct 25. doi: 10.1038/s41375-023-02072.
    PubMed    


  320. V STACKELBERG A, Jaschke K, Jousseaume E, Templin C, et al
    Tisagenlecleucel vs. historical standard of care in children and young adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
    Leukemia. 2023 Oct 25. doi: 10.1038/s41375-023-02042.
    PubMed     Abstract available


  321. WU A, Yen R, Grasedieck S, Lin H, et al
    Identification of multivariable microRNA and clinical biomarker panels to predict imatinib response in chronic myeloid leukemia at diagnosis.
    Leukemia. 2023 Oct 17. doi: 10.1038/s41375-023-02062.
    PubMed     Abstract available


  322. JOHANSSON KB, Zimmerman MS, Dmytrenko IV, Gao F, et al
    Idasanutlin and navitoclax induce synergistic apoptotic cell death in T-cell acute lymphoblastic leukemia.
    Leukemia. 2023 Oct 14. doi: 10.1038/s41375-023-02057.
    PubMed     Abstract available


  323. DEL GIUDICE I, Foa R
    Measurable residual disease in chronic lymphocytic leukemia. Where do we stand?
    Leukemia. 2023 Oct 14. doi: 10.1038/s41375-023-02066.
    PubMed    


  324. ECKARDT JN, Stasik S, Rollig C, Petzold A, et al
    Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia.
    Leukemia. 2023 Oct 13. doi: 10.1038/s41375-023-02061.
    PubMed     Abstract available


  325. OTTONE T, Silvestrini G, Piazza R, Travaglini S, et al
    Expression profiling of extramedullary acute myeloid leukemia suggests involvement of epithelial-mesenchymal transition pathways.
    Leukemia. 2023 Oct 6. doi: 10.1038/s41375-023-02054.
    PubMed     Abstract available


  326. KANTARJIAN HM
    What is the impact of failing to achieve TKI therapy milestones in chronic myeloid leukemia.
    Leukemia. 2023 Oct 5. doi: 10.1038/s41375-023-02053.
    PubMed    


  327. TULKENS D, Boelens M, Naert T, Carron M, et al
    Mutations in the histone methyltransferase Ezh2 drive context-dependent leukemia in Xenopus tropicalis.
    Leukemia. 2023 Oct 4. doi: 10.1038/s41375-023-02052.
    PubMed     Abstract available


  328. CROSS NCP, Ernst T, Branford S, Cayuela JM, et al
    European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia.
    Leukemia. 2023 Oct 4. doi: 10.1038/s41375-023-02048.
    PubMed     Abstract available


  329. JAHN E, Saadati M, Fenaux P, Gobbi M, et al
    Correction: Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients.
    Leukemia. 2023 Oct 3. doi: 10.1038/s41375-023-02017.
    PubMed    


  330. HUBER S, Baer C, Hutter S, Dicker F, et al
    Risk assessment according to IPSS-M is superior to AML ELN risk classification in MDS/AML overlap patients defined by ICC.
    Leukemia. 2023;37:2138-2141.
    PubMed    


  331. OTHMAN J, Potter N, Mokretar K, Taussig D, et al
    FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML.
    Leukemia. 2023;37:2066-2072.
    PubMed     Abstract available


  332. FISHER JG, Doyle ADP, Graham LV, Sonar S, et al
    XPO1 inhibition sensitises CLL cells to NK cell mediated cytotoxicity and overcomes HLA-E expression.
    Leukemia. 2023;37:2036-2049.
    PubMed     Abstract available


  333. CASERTA C, Nucera S, Barcella M, Fazio G, et al
    miR-126 identifies a quiescent and chemo-resistant human B-ALL cell subset that correlates with minimal residual disease.
    Leukemia. 2023;37:1994-2005.
    PubMed     Abstract available


  334. TIAN Z, Shi C, Yang G, Allen JK, et al
    Preclinical development of 1B7/CD3, a novel anti-TSLPR bispecific antibody that targets CRLF2-rearranged Ph-like B-ALL.
    Leukemia. 2023;37:2006-2016.
    PubMed     Abstract available


  335. GURULE NJ, Malcolm KC, Harris C, Knapp JR, et al
    Myelodysplastic neoplasm-associated U2AF1 mutations induce host defense defects by compromising neutrophil chemotaxis.
    Leukemia. 2023;37:2115-2124.
    PubMed     Abstract available


    September 2023
  336. MALIK N, Hay J, Almuhanna HNB, Dunn KM, et al
    mTORC1-selective activation of translation elongation promotes disease progression in chronic lymphocytic leukemia.
    Leukemia. 2023 Sep 29. doi: 10.1038/s41375-023-02043.
    PubMed     Abstract available


  337. JONDREVILLE L, Dehgane L, Doualle C, Smagghe L, et al
    del(8p) and TNFRSF10B loss are associated with a poor prognosis and resistance to fludarabine in chronic lymphocytic leukemia.
    Leukemia. 2023 Sep 26. doi: 10.1038/s41375-023-02035.
    PubMed     Abstract available


  338. FECHINA L, Popov A, Tsaur G, Henze G, et al
    Combination of chemotherapy and all-trans retinoic acid for the treatment KMT2A-rearranged infant acute lymphoblastic leukemia. Results of the MLL-Baby trial.
    Leukemia. 2023 Sep 23. doi: 10.1038/s41375-023-02034.
    PubMed    


  339. KUBASCH AS, Peterlin P, Cluzeau T, Gotze KS, et al
    Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial.
    Leukemia. 2023 Sep 21. doi: 10.1038/s41375-023-02029.
    PubMed    


  340. DOBISH KK, Wittorf KJ, Swenson SA, Bean DC, et al
    FBXO21 mediated degradation of p85alpha regulates proliferation and survival of acute myeloid leukemia.
    Leukemia. 2023 Sep 9. doi: 10.1038/s41375-023-02020.
    PubMed     Abstract available


  341. ECKARDT JN, Bill M, Rausch C, Metzeler K, et al
    Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia - implications for the European leukemia net risk classification.
    Leukemia. 2023 Sep 7. doi: 10.1038/s41375-023-02016.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.